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Critical Structure Sparing in Stereotactic Ablative
Radiotherapy for Central Lung Lesions: Helical
Tomotherapy vs. Volumetric Modulated Arc Therapy
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Abstract
Background: Helical tomotherapy (HT) and volumetric modulated arc therapy (VMAT) are both advanced techniques of
delivering intensity-modulated radiotherapy (IMRT). Here, we conduct a study to compare HT and partial-arc VMAT in their
ability to spare organs at risk (OARs) when stereotactic ablative radiotherapy (SABR) is delivered to treat centrally located
early stage non-small-cell lung cancer or lung metastases.
Methods: 12 patients with centrally located lung lesions were randomly chosen. HT, 2 & 8 arc (Smart Arc, Pinnacle v9.0)
plans were generated to deliver 70 Gy in 10 fractions to the planning target volume (PTV). Target and OAR dose parameters
were compared. Each technique’s ability to meet dose constraints was further investigated.
Results: HT and VMAT plans generated essentially equivalent PTV coverage and dose conformality indices, while a trend for
improved dose homogeneity by increasing from 2 to 8 arcs was observed with VMAT. Increasing the number of arcs with
VMAT also led to some improvement in OAR sparing. After normalizing to OAR dose constraints, HT was found to be
superior to 2 or 8-arc VMAT for optimal OAR sparing (meeting all the dose constraints) (p = 0.0004). All dose constraints were
met in HT plans. Increasing from 2 to 8 arcs could not help achieve optimal OAR sparing for 4 patients. 2/4 of them had 3
immediately adjacent structures.
Conclusion: HT appears to be superior to VMAT in OAR sparing mainly in cases which require conformal dose avoidance of
multiple immediately adjacent OARs. For such cases, increasing the number of arcs in VMAT cannot significantly improve
OAR sparing.
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Excellent OAR sparing has been routinely achieved through
intensity modulated radiotherapy (IMRT), which generates
highly conformal dose avoidance of structures immediately
adjacent to the tumor target in various sites [11,12]. More
recently, advanced techniques of IMRT delivery under image
guidance, helical tomotherapy (HT) [13] and volumetric modulated arc therapy (VMAT) [14,15], have been shown to produce
more conformal dose distribution, and better OAR sparing when
compared to IMRT, or three dimensional conformal radiotherapy (3D-CRT) at various sites [16–24]. Thus, HT & VMAT may
be more suitable when treating centrally located lung lesions with
SABR.
Previously, we have demonstrated the feasibility of HT-based
SABR for centrally located lung lesions which are very close to
critical OARs in the thorax; while VMAT has been shown to be

Introduction
Stereotactic ablative radiotherapy (SABR), or stereotactic body
radiotherapy (SBRT), has been shown to be an excellent treatment
option for early-stage non-small cell lung cancer (NSCLC) and
lung metastases when a biologically effective dose (BED) of
$100 Gy10 is delivered [1–4]. However, treatment related death
from severe pulmonary toxicities, hemoptysis, or esophagitis, has
been reported when various dose fractionation schedules were
delivered to treat centrally located lesions [5–9]. This happened
mainly when a large fractional dose has been delivered, leading to
the overdosing of the organs at risk (OARs) adjacent to the tumor
target. Therefore, respecting the OAR dose constraints is essential
when treating central lesions close to the mediastinal structures to
avoid potentially catastrophic consequences [10].
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superior to IMRT or 3D-CRT for lung SABR in OAR sparing
[22–25]. In this dosimetric study multi-arc VMAT and HT and
compared directly in their ability to maximally spare immediately
adjacent OARs when SABR is delivered to the treat centrally
located lung lesions. In addition, potential benefits of increasing
the number of arcs for VMAT-based SABR in this setting are
explored. In this study, 7 Gy 6 10 fractions was investigated
because it was associated with an excellent toxicity profile when
bulky tumors were treated, and the clinically sound BED achieved
with this dose fractionation schedule (119 Gy10) [26].

Target Volume Delineation
The gross tumor volume (GTV) was delineated at the lung
window level on the treatment planning CT. The clinical target
volume (CTV) was defined as the GTV and its immediately
adjacent areas which were felt to be at a high risk for microscopic
disease extension. The planning target volume (PTV) was the
CTV with a 5 mm expansion to account for set up errors and
residual tumor motion. Particular attention was paid to avoid
overlapping any target volumes with the OARs. In cases for which
4D CT was available, internal target motion was accounted for by
4D CT simulation. The lungs, esophagus, spinal cord, and the
heart were contoured for each patient. The major vessels and
major airway were contoured only when they are adjacent to the
GTV. All the target delineation was performed in the clinical
Pinnacle treatment planning system, version 9.0 (Philips Medical
Systems, Bothell, WA).

Methods
Patient and Tumor Characteristics
This study has been approved by the institutional review board
(IRB) at the University of Arizona. Since no actual human subjects
were involved, no informed consent was needed per IRB. A total
of 12 patients with centrally located lesions have been randomly
identified. These patients had undergone 3D or intensitymodulated SBRT for stage I-II NSCLC or metastasis to the lung
in the department of radiation oncology at the University of
Arizona. Central location is defined as the area within 2 cm of the
proximal bronchial tree, which includes the lower trachea, carina,
mainstem bronchi, and the lobar bronchi. The critical structures
are the esophagus, the heart, the spinal cord, major vessels in the
mediastinum, and the major airway (lower trachea, carina,
mainstem bronchi, and lobar bronchi). The tumor location, size,
and its immediately adjacent OARs in each case are listed in
Table 1.

Treatment Planning
Tomotherapy plans were generated in the Tomotherapy Hi-Art
planning system using 6 MV photons delivered without a
flattening filter. Longitudinal aperture size of 1.05 cm or 2.5 cm,
a pitch of 0.3, and a modulation factor of 3 were used. Please refer
to our previous study for details [25]. VMAT plans are generated
with Smart Arc (SA) using the clinical version 9.0 of Pinnacle to be
delivered with 6 MV photons. The machine specification of a
Varian linear accelerator with 120 leaf interdigitating MLC is
used. VMAT plans were generated with coplanar partial arcs to
spare as much contralateral lung as possible. The arc length varied
from 150u to 240u. 2-arc and 8-arc plans were created for each

Table 1. Patient tumor characteristics.

Patients

Location

PTV volume (cc)

Immediately adjacent structures

PTV to structure distance (cm)

1

RLL

153.68

Heart

0.15

2

LUL

70.54

Aortic arch

1.06

L pulmonary artery

0.11

3

RUL

69.22

Heart

0.50

SVC

0.23
1.22

4

RML

14.04

Heart
R middle lobar bronchus

0.10

5

RUL

56.52

R mainstem bronchus

0.20

R pulmonary artery

0.23

6

RUL

34.91

R brachiocephalic artery

0.19

7

LUL

22.79

Aorta

0.11

8

RUL

133.64

9

RUL

147.22

10

RLL

65.76

Esophagus

1.30

SVC

0.26

Trachea

1.06

Heart

1.54

R pulmonary artery

0.39

Esophagus

0.53

Heart

0.13

R pulmonary artery

0.22

11

LUL

24.11

Aortic arch

0.10

12

RML

22.69

Heart

0.23

R middle lobar bronchus

0.14

R pulmonary vein

0.97

doi:10.1371/journal.pone.0059729.t001
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Figure 1. Illustration of the possible scenarios of dose conformity described by the conformation number (CN). The shade represents
the target volume, the dotted line represents the desired isodose, the small solid in c) represent a critical structure that is immediately adjacent to the
target. a). the ideal dose conformation with CN = 1. b). Less than optimal coverage of the target volume. c). In situations where the target is next to a
critical structure, both adequate dose coverage of the target and the sparing of the critical structure are desired. As a result, more healthy tissue is
irradiated in the context of the healthy tissue dose constraint as shown. The CN will be ,1 is both b) and c).
doi:10.1371/journal.pone.0059729.g001

case. For 2- arc plans, the delivery time was constrained to 3
minutes. Delivery time was not limited for 8-arc plans. Continuous
gantry motion, dose-rate variation, and MLC motion were
approximated by optimizing individual beams at 4u gantry angle
increments. The machine configuration was based on the
‘‘Recommended Smart Arc Physics Parameters’’ from Philips
(Andover, MA. Recommended Smart Arc Physics Parameters.
Philips Application Note 2009-03 Rev. A). Except that the ‘‘Max
MU’’ limitation, which is 999 by default, has been changed to
5999.
All SABR plans prescribed 70 Gy delivered in 10 daily fractions
to the PTV with heterogeneity corrections. They were optimized
to have at least 95% of the PTV receiving 100% of the
prescription dose with collapsed-cone convolution (CCC) algorithm for both HT and SA. Please refer to our previous study for
details on the dose constraints used [27]. PTV coverage took
precedence over OAR sparing in all plans. All treatment plans
were designed under the same set of planning guidelines agreed
upon among the authors with similar levels of emphasis placed on
the PTV and the OARs. HT planning was conducted at the
University of Arizona, and VMAT planning was conducted at the
Cancer Hospital & Institute at Peking Union Medical College. In
addition, all the plans were designed to deliver a dose that is used
in daily clinical practice.

Plan Comparison
Various lung dose parameters and the maximum dose (Dmax) to
specific OARs generated in HT and VMAT plans were compared
to assess their ability for OAR sparing. For the PTV, the dose
covering 95% of the PTV (D95), the % PTV receiving $70 Gy
(V70 Gy), the mean dose (Dmean) & Dmax, the homogeneity index
(HI), and the conformation number (CN) were generated and
compared between different techniques. The HI and CN are
previously defined [28], and are described below:
HI~(D2 {D98 )=Dp |100%,

CN~ðPTV encompassed by 95% isodose=PTVÞ|
(PTV encompassed by 95% isodose=95% isodose volume),

ð1Þ

ð2Þ

D2 and D98 represent the doses to 2% and 98% of the PTV, Dp is
the prescription dose. For the CN, the first portion (1st
parentheses) is an assessment of target volume coverage by 95%
of the prescription dose; and the second part (2nd parentheses) is an
assessment of normal tissue sparing (the volume of normal tissue
receiving $95% of the prescribed dose). The CN values between 0
and 1 with 1 representing the ideal conformity (Fig. 1a). In other

Table 2. Comparison of PTV dose coverage parameters generated through helical tomotherapy, VMAT with 2 arcs, and 8 arcs with
absolute doses illustrated in mean 6 standard deviation.

P value

VMAT
HT

2 Arcs

8 Arcs

HT vs. 2 Arcs

HT vs. 8 Arcs

2 Arcs vs. 8 Arcs

PTV dose coverage parameters
D95 (Gy)

70.6160.61

70.0060.00

70.0060.00

0.0003

0.0003

0.99

96.1561.22

95.0060.00

95.0060.00

0.0006

0.0006

0.99

Dmean (Gy)

74.0361.74

76.1261.53

74.9961.69

0.002

0.11

0.06

Dmax (Gy)

81.9863.66

82.7662.77

80.7662.39

0.46

0.26

0.07

CN

0.6460.06

0.6160.11

0.6360.11

0.17

0.73

0.29

HI

19.23610.95

21.4566.66

17.8365.75

0.24

0.45

0.06

V70

Gy

(%)

doi:10.1371/journal.pone.0059729.t002
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Table 3. Comparison of lung dosimetric parameters generated through helical tomotherapy, VMAT with 2 arcs, and 8 arcs with
absolute doses illustrated in mean 6 standard deviation.

P value

VMAT
HT

2 Arcs

8 Arcs

HT vs. 2 Arcs

HT vs. 8 Arcs

2 Arcs vs. 8 Arcs

Total lung
MLD (Gy)

6.4862.33

7.2363.47

6.5062.53

0.24

0.97

0.25

V5

21.1668.03

22.89610.15

22.3169.25

0.23

0.42

0.68

V10

15.8865.48

15.1666.18

14.6265.78

0.38

0.13

0.51

V20

10.4964.16

10.2764.12

9.9463.86

0.82

0.57

0.73

Ipsilateral lung
MLD (Gy)

10.7263.67

12.7064.98

12.0364.50

0.03

0.15

0.45

V5

34.10613.29

38.22614.09

37.64613.66

0.03

0.06

0.75

V10

28.35611.11

30.19610.90

27.93610.36

0.42

0.15

0.32

V20

19.5068.81

21.4268.06

20.7867.68

0.36

0.54

0.76

MLD (Gy)

1.6260.75

1.6460.76

1.6060.67

0.90

0.95

0.85

V5

7.0466.27

8.7667.10

8.1065.70

0.36

0.57

0.72

V10

2.1162.88

1.1161.11

0.9861.16

0.06

0.04

0.79

V20

0.2760.42

0.0460.09

0.0560.07

0.04

0.04

0.98

Contralateral lung

doi:10.1371/journal.pone.0059729.t003

situations that may be encountered in SABR delivery, a less-thanideal CN is achieved when the target is partially covered by the
desired dose with proportionately increased irradiation of the
healthy tissue (Fig. 1b); or increased volume of healthy tissue may
be irradiated within the limit of the allowed dose constraints due to
the need to adequately cover the target volume and to spare a
critical structure that is in its proximity (Fig. 1c).
The differences in tumor characteristics, such as tumor size and
the distance between the PTV & its immediately adjacent
structures, were sought between the group of patients for whom
optimal PTV coverage and OAR sparing was achieved (Group 1)
and those whose plans were suboptimal (Group 2). Group 1
included both HT and VMAT plans (2 and/or 8 arc plans). Group
2 included patients for whom either the HT or both VMAT plans
could not successfully spare $1 immediately adjacent OAR if
adequate PTV coverage was maintained.

Statistical Analysis
Dosimetric parameters generated in the HT, 2-arc, and 8-arc
plans were compared through a randomized complete block
ANOVA. After the dose parameters for the OARs and the target
volumes were obtained from the HT and the VMAT plans, they
were normalized to the OAR dose constraints listed in Table 2.
Selected OAR dose parameters from the HT, and VMAT plans
were compared using multifactorial ANOVA while controlling
for differences between patients and various OARs. In the
assessment of each treatment technique’s influence on OAR
sparing, multiple logistic regression was then performed on these
selected normalized parameters. In analyzing the differences in
tumor characteristics between groups 1 & 2, one-way ANOVA
was used. Statistical significance was defined by a p value ,0.05.
All analyses were performed using JMP-Pro/v9.0.2 (SAS Institute
Inc., Cary, NC).

Table 4. Comparison of the maximum dose other organs at risk (OARs) generated through helical tomotherapy, VMAT with 2 arcs,
and 8 arcs with absolute doses illustrated in mean 6 standard deviation.

P value

VMAT
HT

2 Arcs

8 Arcs

HT vs. 2 Arcs

HT vs. 8 Arcs

2 Arcs vs. 8 Arcs

Dmax for other OARs (Gy)
Spinal cord

18.8467.44

14.1868.57

13.6568.20

0.03

0.02

0.79

Esophagus

22.72613.06

22.71613.52

22.28611.84

0.99

0.62

0.62

Heart

23.08622.83

29.77626.70

29.66626.54

0.02

0.03

0.97

Major airway

34.10615.02

37.97617.37

37.30617.09

0.07

0.12

0.74

Major vessels

46.3063.20

50.9166.51

49.0365.35

0.01

0.09

0.24

doi:10.1371/journal.pone.0059729.t004
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Figure 2. Comparison of dose parameters to the organs at risk. Organs at risk: a) Esophagus, b) heart, c) major airway, d) major vessels, e)
spinal cord, f) and g) mean lung dose (MLD) and V20 for the total lung, after normalized to the absolute dose constraints between helical tomotherapy
(Tomo), 2-arc, and 8-arc VMAT plans.
doi:10.1371/journal.pone.0059729.g002

favoring HT for all OARs as an aggregate, when compared with
VMAT techniques (p = 0.0004); specifically affecting MLDtotal
(p = 0.0219), and Dmax to the heart (p = 0.0219) & the major vessels
(p = 0.0033). OAR sparing was successfully achieved in all HT
plans. However, OAR overdosing was found in 2 &/or 8-arc plans
in patients 3, 9, 10, 11, 12 (Fig. 2). Increasing from 2 to 8 arcs
decreased the esophageal Dmax for patient 10, and the MLDtotal
for patient 3 to below the dose threshold (Fig. 2a, f). The same did
not occur for the heart, the major airway, the major vessels, and
the MLDtotal for patients 9, 10, 11, and 12 (Fig. 2b, c, d, and f).
However, increasing from 2 to 8 arcs decreased the Dmax to the
major vessels and the spinal cord in many cases (Fig. 2d, e).

Results
HT and VMAT SABR plans were generated for all 12 patients
to meet the PTV dose coverage criteria. The PTV, lung, and other
OARs’ dose parameters generated with each treatment approach
are summarized in Tables 2, 3, and -4, respectively, with any two
different techniques compared directly.

HT vs. 2-arc VMAT
For the PTV, D95 and V70 Gy were significantly higher in the
HT plans (Table 2). HT also generated significantly lower Dmean
(p = 0.002). No significant difference in the Dmax, CN, and HI was
found. For the total lung (volume of both lungs – GTV), no
significant differences in the mean lung dose (MLD), V5, V10, and
V20 was observed (Table 3). The ipsilateral MLD and V5 were
significantly lower in HT plans (p = 0.03, 0.03, respectively). On
the contrary, 2-arc VMAT achieved lower V20 in the contralateral
lung (p = 0.04). HT generated significantly lower Dmax for the
heart and the major vessels (p = 0.02, 0.01, respectively), while a
trend toward lower Dmax for the major airway was observed
(p = 0.07) (Table 4). However, lower Dmax to the spinal cord was
found in VMAT plans (p = 0.03).

Tumor Characteristics for Patients for Whom Neither
VMAT Plans Achieved Optimal OAR Sparing
The tumor characteristics for group 2 (patients 9–12) were
compared with those for group 1 (patients 1–8). Given the small
sample size for each group, no significant difference was found in
PTV diameter, volume, and distances to the closest and furthest
immediately adjacent OARs (Table 5). 2/4 cases in group 2 had 3
immediately adjacent structures (50%), while only 2 such cases
were found in group 1 (25%). The median PTV to its closest OAR
distance was also slightly shorter in group 2 when compared with
group 1 (0.13 cm vs. 0.17 cm).

HT vs. 8-arc VMAT
Significantly higher D95 and V70 Gy for the PTV for HT was the
only observed difference in the target dose indices (Table 2). Totallung dose parameters were equivalent, while the contralateral V10
& V20 was significantly lower in VMAT plans (p = 0.04, 0.04,
respectively) (Table 3). For other OARs, HT achieved lower Dmax
to the heart, while VMAT achieved lower Dmax to the spinal cord
(p = 0.03, 0.02, respectively) (Table 4).

Discussion
Although higher D95 and V70 Gy were found in HT plans, this is
mostly due to the differences in how target coverage parameters
were executed in the treatment planning systems (TPS) under
comparison. No significant difference in dose conformality was
found between HT and VMAT plans. However, increasing from 2
to 8 arcs led to a trend toward lower PTV Dmean, Dmax, and HI
(Table 2). Thus, suggesting a potential for improving dose
homogeneity by increasing the number of arcs when treating
targets in areas of complex geometry with VMAT. This finding is
consistent with what has been previously observed by Guckenberger et al [29]. Poor CN has been found with all three
different techniques (Table 2). The CN achieved in our VMAT
plans was lower than what has been reported in the literature [22].
This may be partially due to the degree of complexity in OAR
sparing in close vicinity to the target; which is especially true when
multiple OARs are immediately adjacent to the PTV, making it
extremely difficult to conform the dose to the PTV in all
directions. In these cases, less conformity is observed due to
increased dose to the healthy tissue that has the least demanding

2-arc vs. 8-arc VMAT
For the PTV, a trend toward significance for lower Dmean,
Dmax, and HI were observed (p = 0.06, 0.07, 0.06, respectively)
(Table 2). No significant difference between the 2 & 8-arc plans
was found in any of the OAR parameters (Tables 3 & 4).

Dmax for Adjacent OARs and MLD, V20 for the Total Lung
((MLDtotal, V20, total) after Normalizing to the Dose
Constraints Used
No statistically significant difference between the three different
techniques was observed in the normalized dose parameters when
patient and OAR differences were controlled (Fig. 2). However,
the treatment technique was found to be a statistically significant
factor influencing OAR sparing (meeting dose constraints),

Table 5. Tumor characteristics for groups of patients for whom optimal OAR sparing and tumor volume dose coverage can be
achieved with HT or any one form of VMAT (Group 1) and those patients among whom optimal OAR sparing cannot be achieved if
optimal tumor volume coverage is desired with VMAT (Group 2).

PTV diameter (cm)

PTV volume (cc)

Number of immediately
adjacent normal structures

Shortest distance
to the PTV (cm)

Longest distance to the
PTV (cm)

Group 1

6.0561.90

69.42650.46

1.8860.84

0.1760.06

0.6160.50

Group 2

5.9461.74

65.07658.61

2.2560.96

0.1960.13

0.7960.62

doi:10.1371/journal.pone.0059729.t005
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Figure 3. Illustration of a comparison of the 2 and 8 Arc plans demonstrating that the shape of the isodose covering the PTV is
largely dependent on the immediately adjacent critical structures (yellow and blue) that need to be spared in one patient. As a
result, slightly increased volume of the normal lung tissue is included in the high dose volume lateral to the PTV (blue shade) away from the central
structures. Also shown here is that when comparing to the 2 Arc plan, the high dose region included by the 77 Gy isodose in the 8 Arc plan is greatly
diminished, demonstrating increased homogeneity.
doi:10.1371/journal.pone.0059729.g003

constraints favoring HT over VMAT. Optimal OAR sparing was
achieved in all cases by HT, but only the first 8 cases for VMAT
(Fig. 2). Increasing from 2 to 8 arcs helped to meet the dose
constraints for certain structures for patients 3 & 10 (Fig. 2 a, f),
and decreased Dmax for the spinal cord and the major vessels in
many cases (Fig. 2 d, e). This did not lead to meeting the dose
constraints for all immediately adjacent OARs for patients 9–12,
among whom increased number of immediately adjacent structures and short distance between PTV and the closest OAR were
common. No statistically significant difference in tumor characteristics was found between patients 9–12 and patients 1–8 due to
the small number of patients studied (Table 5). However, our
findings suggest that HT may be more appropriate in cases which
demand conformal dose avoidance of multiple structures ($2) that
are very close to the PTV in the delivery of SABR for centrally
located lung lesions, even though increasing the number of arcs in
VMAT may improve OAR sparing in certain situations. Our
findings are corroborated in a study comparing HT and VMAT in
delivering conventionally fractionated radiotherapy in several
body sites by Rong et al, which demonstrated improved target
dose homogeneity and lower doses to more critical structures in
the HT plans [28]. This is mainly due to the increased freedom of
intensity modulation created by delivering image-guided IMRT
under synchronous gantry rotation and couch motion with HT
[13,25].
Although shown to be more capable of OAR sparing in setting
of lung SABR for central lesions, HT is associated with much
longer fractional treatment delivery time of .40 minutes for each
case, mainly attributing to the complexity of intensity modulation
required. Due to this fact, the exact treatment time for the HT
plans was not recorded. On the other hand, 2 & 8 arc VMAT had
average fractional treatment delivery times of only 180 & 331
seconds, respectively. Thus, VMAT remains to be more desirable

dose constraint in the context of each specific case as previously
shown in Fig. 1c. This is also illustrated in Figure 3, where the
desired isodose can be seen to include additional normal lung
tissue due to the sparing of immediately adjacent normal
structures. In the same illustration, increased dose homogeneity
from the 8-Arc plan is also shown as the 77 Gy isodose is
significantly diminished when compared with the 2-Arc plan.
Thus, supporting that dose homogeneity may be improved by
increasing the number of arcs.
Lung dose parameters in HT and VMAT plans are shown in
Table 3. VMAT plans demonstrated significantly lower contralateral lung dose parameters when compared to HT plans
(Table 3). This can possibly be explained by the difference in
the degree of the arc generated in 2 different TPS, which is partial
arc for VMAT and full arc for HT. Due to the already very low
values of the contralateral lung dose parameters, VMAT’s
potentially improved contralateral lung sparing may not be of
any clinical significance. For the ipsilateral lung, potential factors
of clinical relevance, the V5, and MLD, were significantly lower in
HT plans when compared to 2-arc plans [30]. However, this
significance was lost when HT and 8-arc plans were compared.
Similar to what was observed for the ipsilateral lung, HT has
demonstrated significantly lower Dmax to the major vessels than 2arc VMAT. However, this significance was lost when HT was
compared to 8-arc VMAT. Although no significant difference was
observed in any OAR dose parameters between 2 & 8 arcs VMAT
plans, these observations again suggest that increasing from 2 to 8
arcs for VMAT-based SABR may have a potential for improving
conformal dose avoidance in areas of complex geometry.
With patient and OAR differences controlled, no difference in a
series of normalized dosimetric parameters was found between the
three techniques (Fig. 2). However, the technique used was found
to be a significant factor influencing the ability to meet OAR dose
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for targets in areas of relatively less complex geometry. The
prolonged treatment time associated with HT can be potentially
improved by implementing the dynamic jaw and dynamic couch
feature [31]. At the current time, this remains a problem for
HT-based SABR mainly because of its associated increase in
intrafractional motion, which can be critical when treating
central lesions with SABR. As a result, proper respiratory
motion management and careful body immobilization are
essential [32,33]. In our experience, 4D CT simulation to
account for tumor motion in various locations remains the most
straight forward approach for respiratory motion management
for HT clinically. Furthermore, treatment efficiency can be
improved by dividing the fractional dose into two consecutive
fractions (7 Gy delivered in 2 consecutive fractions, 3.5 Gy/
fraction) [34].
The dose delivery & calculation accuracy have been commented elsewhere, which were found to be adequate for both VMAT
and HT [28]. In a study by Takahashi et al, the CCC algorithm
closely approximated the Monte Carlo algorithm in the dose
calculation specific for lung SBRT [35]. This warrants the validity
of SABR dose calculation for both HT and VMAT, which is also
critical in the setting of centrally located lesions closely surrounded
by multiple critical OARs. Early clinical reports on treating mostly
peripheral lesions with HT-based and VMAT-based SABR have
been promising [34,36]. A prospective clinical study investigating

how to best apply these advanced techniques in the treatment of
central lung lesions with SABR will be conducted in the near
future.
Due the virtual nature of this dosimetric study, no further
quality assurance is conducted. However, treatment planning
accuracy for VMAT and HT are implied from studies conducted
in the past (25, 37). But it will be done as part of a prospective
study in the future.

Conclusion
In delivering SABR or SBRT for centrally located lung lesions,
HT appears to be superior to VMAT in OAR sparing mainly for
targets with multiple immediately adjacent structures. Although
increasing arc number cannot achieve the aim of sparing all the
OARS in cases associated with complex geometry, it may help
lowering the doses to them. However, VMAT may be preferred
over HT in cases of simpler geometry due to much shorter
treatment delivery time.
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